The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.
This article was originally published on MedicalXpress.com
FDA approves Caplyta for major depressive disorder in adults
You may also be interested in:
The Latest
Avoiding Common Relationship Mistakes for a Happier Love Life
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
The Latest
Microneedling Services in Edmonton: Benefits, Treatment Cost, and How It Works
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Read More:
-
Drinking beverages sweetened with sugar can lead to obesity, cardiovascular disease, cavities, diabetes and other health problems. More than 20 years of public health campaigns [...]
-
Methylphenidate helps the brain to regulate focus and impulse control. It is the most commonly used medicine for ADHD and is the active substance in [...]
-
A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote [...]
